The pharmacological treatment of acquired nystagmus.

Abstract

We review the latest literature on the neuropharmacological treatments for acquired nystagmus.Nystagmus may have a significant [corrected] impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.

• Authors: Arpan R Mehta, Christopher Kennard
• Journal: Practical neurology (Pract Neurol) Vol. 12 Issue 3 Pg. 147-53 (Jun 2012) ISSN: 1474-7766 [Electronic] England
• PMID: 22661344 (Publication Type: Journal Article, Review)

Chemical References

• Amines
• Aminopyridines
• Cyclohexanecarboxylic Acids
• gamma-Aminobutyric Acid
• Gabapentin
• Baclofen
• Memantine

Topics

• Amines (therapeutic use)
• Aminopyridines (therapeutic use)
• Baclofen (therapeutic use)
• Cyclohexanecarboxylic Acids (therapeutic use)
• Gabapentin
• Humans
• Memantine (therapeutic use)
• Nystagmus, Congenital (diagnosis, drug therapy)
• Nystagmus, Pathologic (diagnosis, drug therapy)
• Randomized Controlled Trials as Topic (methods)
• Treatment Outcome
• gamma-Aminobutyric Acid (therapeutic use)